Treatment of Peripheral Arterial Hemorrhage With Lava LES (The LAVA Study)

Inclusion Criteria: * Age ≥18 years; * Active arterial bleeding in the peripheral vasculature, documented on a suitable imaging study; * Subject or subject's legally authorized representative is able and authorized to provide written informed consent for the procedure and the study; * Subject is willing and able to comply with the specified follow-up evaluation schedule; * Life expectancy \>30 days; * No prior embolization in the target territory. Exclusion Criteria: * Pregnancy or breast feeding. A woman who, in the Investigator's opinion, is of child-bearing potential must have a negative pregnancy test within 7 days before the index procedure; * Coexisting signs of peritonitis or other active infection; * Participation in an investigational study of a new drug, biologic or device that has not reached its primary endpoint at the time of study screening; * Uncorrectable coagulopathies such as thrombocytopenia \<40,000/ μL, international normalization ratio (INR) \>2.0; * Contraindication to angiography or catheterization, including untreatable allergy to iodinated contrast media; * Anatomic arterial unsuitability such that, in the Investigator's opinion, the delivery catheter cannot gain access to the selected position for safe and intended embolization; * Known allergy or other contraindication to any components of Lava LES including dimethyl sulfoxide (DMSO); * More than 4 Target Lesions will require embolization, in the Investigator's opinion after performance of diagnostic angiography or another suitable imaging study.